fda compounding semaglutide update The is proposing the removal of three GLP-1 drugs from the 503B bulks list of active ingredients that outsourcing facilities can use to make compounded medicines, the agency announced on Thursday The FDA's Decision to Ban

To view or add a comment, sign in Glad to see decisive action from the FDA

Current Medicinal Chemistry

MDA, LPCAT3, and prostaglandin-endoperoxide synthase 2 (PTGS2) expression were significantly increased, promoting neuronal ferroptosis and lipid peroxidation in EAE mice

Getting it wrong doesn't just waste a vial

Your best choice depends on your medical background, how your body responds, which side effects you can handle, and what you can afford

Differences in Characteristics and Complications for GLP-1 Users Patients taking GLP-1 medications were more likely to have comorbidities including type 2 diabetes, hypertension, and chronic obstructive pulmonary disease, although body mass index was similar between groups